Abstract:Loss-of-function mutations in methyl-CpG binding protein 2 (MECP2) cause Rett syndrome, a postnatal neurodevelopmental disorder that occurs in ~1/10,000 live female births. MeCP2 binds to methylated cytosines across genomic DNA and recruits various partners to regulate gene expression. MeCP2 has been shown to repress transcription in vitro and interacts with co-repressors such as the Sin3A and NCoR complexes. Based on these observations, MeCP2 has been largely considered as a repressor of transcription. However, a mouse model of RTT displays many down-regulated genes, and those same genes are up-regulated in a MECP2 duplication mouse model. Furthermore, TCF20, which has been associated with transcriptional activation, have recently been identified as a protein interactor of MeCP2. These data broaden the potential functions of MeCP2 as a regulator of gene expression. Yet, the molecular mechanisms underlying MeCP2-dependent gene regulation remain largely unknown. Here, using a human MECP2 gain-of-function Drosophila model, we screened for genetic modifiers of MECP2-induced phenotypes. Our approach identified several subunits of the Drosophila super elongation complex, a P-TEFb containing RNA polymerase II (RNA pol II) elongation factor required for the release of promoter-proximally paused RNA pol II, as genetic interactors of MECP2. We discovered that MeCP2 physically interacts with the SEC in human cells and in the mouse brain. Furthermore, we found that MeCP2 directly binds AFF4, the scaffold of the SEC, via the transcriptional repression domain. Finally, loss of MeCP2 in the mouse cortex caused reduced binding of AFF4 specifically on a subset of genes involved in the regulation of synaptic function, which also displayed the strongest decrease in RNA pol II binding in the genebody. Taken together, our study reveals a previously unrecognized mechanism through which MeCP2 regulates transcription, providing a new dimension to its regulatory role in gene expression.

The methyl-CpG-binding domain (MBD) is crucial for MeCP2's dysfunction-induced defects in adult newborn neurons.

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

Loss of MeCP2 in immature neurons leads to impaired network integration.

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

MeCP2 links heterochromatin condensates and neurodevelopmental disease

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

Expression of Phospho-MeCP2s in the Developing Rat Brain and Function of Postnatal MeCP2 in Cerebellar Neural Cell Development

Differential dynamics specify MeCP2 function at nucleosomes and methylated DNA

Electrophysiological Phenotypes of MeCP2 A140V Mutant Mouse Model